Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

MedImmune Deploys Targeted Antibodies In Battle Against Superbugs

Executive Summary

Using the ICAAC annual meeting as a platform, MedImmune execs explain efforts to reinvigorate the company’s infectious disease pipeline. Early data suggest a possible supporting role for monoclonal antibody candidates in preventing and treating bacterial infections.

You may also be interested in...



AstraZeneca Straddles The Fence On Antibiotics; Is It About To Fall Off?

The big pharma denies reports it is disbanding antibiotics research, but says it is continuing to explore partnering opportunities for its non-core portfolio, including infectious disease.

Epidemiology First: MedImmune Moving Ahead With Preventive Antibodies, But Needs More HAP Data

The biotech’s senior VP for infectious disease and vaccine R&D says prevention must be a part of fighting antimicrobial resistance, but moving the new approach into advanced trials first requires getting a handle on the incidence of hospital-acquired pneumonia in intensive care patients.

Deals Of The Week Looks At The Intersection Of Patient Empowerment, Generic Drugs And Macaroni & Cheese

Over one-third of practicing physicians cave in to patient requests for a brand-name drug over a generic, but can the trend hold? Also, deals by Baxter/Xenetic, AstraZeneca/FOB, Galectin/SBH, Biogen/UCB and Actavis/Zhejiang Chiral Medicine Chemicals.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS054753

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel